Every week, the average person may swallow roughly five grams of plastic, about the weight of a credit card, according to a 2019 analysis commissioned by the World Wildlife Fund. Most of those tiny fragments pass through the gut. Some do not. A growing body of autopsy evidence shows that micro- and nanoplastics lodge in human organs, including the brain. Now a team of South Korean researchers has found that a single bacterial strain pulled from traditional kimchi can double the amount of nanoplastic that mice expel in their feces, raising the question of whether a fermented-food microbe could one day help the body take out its own plastic trash.
The kimchi strain and what it did in mice
The bacterium is Leuconostoc mesenteroides CBA3656, a lactic acid species originally cultured from Korean kimchi. In a study published in Bioresource Technology in early 2026, researchers at Chung-Ang University exposed the strain to polystyrene nanoplastics in the lab and found that it physically bound to the particles. That grip held up through a simulated human gastrointestinal tract, where shifting pH and digestive enzymes would normally dislodge loosely attached material.
The team then moved to a mouse model. Animals that received the bacterium excreted roughly twice the volume of nanoplastics compared with untreated controls. The implication: the microbe acts as a biological shuttle, latching onto plastic in the gut and ferrying it out before the particles can cross the intestinal lining into the bloodstream.
Why gut-level removal matters
The urgency behind this line of research comes from what scientists are finding in human tissue. A 2024 study in Nature Medicine used pyrolysis gas chromatography-mass spectrometry to measure plastic in post-mortem organs. The results showed micro- and nanoplastic concentrations in brain samples that significantly exceeded levels detected in liver and kidney. Strikingly, samples collected in more recent years contained higher concentrations than older ones, suggesting that the human plastic burden is climbing over time.
An accompanying editorial in Nature Medicine put the challenge bluntly: the scientific community still lacks a clear picture of how microplastics affect human health, and exposure sources remain under active regulatory scrutiny. The European Commission adopted restrictions on intentionally added microplastics in consumer products in 2023, with phased implementation underway, but dietary and environmental exposure routes are far harder to control.
That gap is what makes the gut an appealing intervention point. Separate laboratory work has shown that common plastics interact with human gut microbiota during simulated digestion, shifting microbial community composition. Other in-vitro experiments demonstrate that microplastics carry bound chemicals and metals that leach under simulated gastrointestinal conditions. If a bacterium binds tightly to plastic before those hitchhiking chemicals are released, it could theoretically reduce both particle and chemical exposure in a single step.
The long list of unknowns
No human trial data exist for this strain as a microplastic-removal agent. The mouse experiments used controlled-microbiome animals, which bear little resemblance to the dense, competitive bacterial ecosystem of an adult human gut. Whether CBA3656 can survive stomach acid during a typical meal, outcompete hundreds of resident species for binding sites, and still adsorb meaningful quantities of plastic in someone eating a mixed diet are all open questions.
The study also tested only polystyrene nanoplastics. Real-world exposure involves a jumble of polymers: polyethylene, polypropylene, PET, nylon, and others, each with different surface chemistry and size profiles. A bacterium that clings well to polystyrene may behave differently with polyethylene film fragments or PET fibers shed from clothing. No comparative data across polymer classes have been published for this strain.
Diet adds another variable. Research in mice has shown that polyethylene microplastics combined with a Western-style diet worsened effects on intestinal homeostasis compared with microplastics alone, suggesting that the same bacterial intervention could produce different outcomes depending on what else a person eats. That interplay between diet, gut flora, and plastic binding has not been mapped in any controlled human setting.
Then there is the question of time. The autopsy data captured plastic concentrations at a single snapshot per individual. No study has tracked living subjects over months or years to determine whether repeated bacterial dosing slows the migration of nanoplastics from gut to bloodstream to brain. Without that longitudinal evidence, doubling fecal excretion in mice cannot be translated into a human health benefit.
Safety deserves scrutiny, too. Leuconostoc species are generally regarded as safe in fermented foods, but delivering a single strain at high doses for a targeted binding function is a different proposition from eating kimchi with dinner. The Bioresource Technology paper reported no serious adverse effects in mice, yet subtle impacts on nutrient absorption, immune signaling, or drug interactions would require dedicated investigation in people.
What this means right now
The strongest takeaway from the Bioresource Technology paper is narrow but real: a food-grade bacterium can bind polystyrene nanoplastics and accelerate their removal from a living animal’s gut. That is a well-controlled proof of concept, not a clinical breakthrough. The study answered a specific mechanistic question and was not designed to measure downstream organ accumulation, chemical desorption, or long-term safety.
For anyone tempted to reach for a probiotic supplement, the current evidence does not support using commercial products to “cleanse” microplastics from the body. Even supplements containing Leuconostoc species are unlikely to match the exact strain, dosage, or preparation used in the mouse experiments. The leap from a controlled animal study to a consumer health strategy is one that no published data yet bridge.
Future research will need to move in stages: confirming binding across a wider range of polymers, testing realistic diets and mixed-plastic exposures in animal models, and eventually running carefully monitored human trials. Several groups beyond the Chung-Ang team are exploring microbial and enzymatic approaches to plastic degradation, but none have reached clinical testing as of mid-2026.
Where the practical leverage still sits
Until gut-level interventions are validated in people, the most concrete actions remain upstream of the intestine. Policies that limit microplastic release at the source, food packaging redesigns that reduce particle shedding, and better filtration of drinking water all target exposure before plastic ever reaches the gut. At the individual level, reducing reliance on single-use plastics, avoiding plastic contact with hot food and liquids, and supporting regulations aimed at curbing environmental contamination rest on firmer ground than any experimental probiotic strategy.
Still, the kimchi bacterium results point to something genuinely new: the possibility that elements of traditional fermented foods might eventually inform biomedical tools for a distinctly modern problem. For now, Leuconostoc mesenteroides CBA3656 is best understood as a research probe, a living handle that scientists can use to study how plastics move through, and sometimes out of, the body. The next step is finding out whether that handle works when the body in question is human.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
